Theres no known major interaction between GLP-1 drugs and common antidepressants
Higher Risks of Gastrointestinal Effects in Diabetic Patients In October 2023, The Journal of the American Medical Association(JAMA), examined adverse events in patients with diabetes associated with GLP-1 RA in a research letter called Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss where it concluded that studies have found increased risks of gastrointestinal adverse events, such as biliary disease, pancreatitis, bowel obstruction, and gastroparesis
Rather than constantly thinking about their next meal or fighting cravings, they report being able to stop eating when satisfied. That reported drop in food noise tracks with peptide YYs known role: the hormone reduces food intake and extends fullness after a meal, and combined with cholecystokinin and GLP-1, reinforces the bodys normal post-meal signaling
Liang L, Hur J, Kang JY, Rhee CK, Kim YK, Lee SY
Can I use a lower dose long-term to maintain my weight loss